Raymond James Downgrades Apellis Pharmaceuticals to Market Perform

Benzinga Newsdesk www.benzinga.com Negative 92.7%

Neg 92.7% Neu 0% Pos 0%

Raymond James analyst Ryan Deschner downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Outperform to Market Perform.

Comments

No comments yet. Be the first!